Galmed Pharmaceuticals (GLMD) Gains from Sales and Divestitures (2016 - 2020)

Galmed Pharmaceuticals' Gains from Sales and Divestitures history runs 4 years deep, the most recent figure standing at $2781.0 for Q4 2020.

• In Q4 2020, Gains from Sales and Divestitures fell 95.1% year-over-year to $2781.0; the TTM figure through Dec 2020 stood at $2781.0 (down 95.1% YoY), while the FY2020 annual figure was $2781.0, down 95.1% from the prior year.
• Gains from Sales and Divestitures was $2781.0 for Q4 2020 at Galmed Pharmaceuticals, down from $56747.0 in the prior quarter.
• In the past five years, Gains from Sales and Divestitures ranged from a high of $78750.0 in Q4 2016 to a low of $2781.0 in Q4 2020.
• Historically, Gains from Sales and Divestitures has averaged $44935.0 across 4 years, with a median of $49104.5 in 2018.
• The sharpest annual moves came in 2019 and 2020: Gains from Sales and Divestitures soared 36.87% in 2019, then slumped 95.1% in 2020.
• A 4-year view of Gains from Sales and Divestitures shows it stood at $78750.0 in 2016, then sank by 47.35% to $41462.0 in 2018, then surged by 36.87% to $56747.0 in 2019, then plunged by 95.1% to $2781.0 in 2020.
• The last three Gains from Sales and Divestitures figures came in at $2781.0 (Q4 2020), $56747.0 (Q4 2019), and $41462.0 (Q4 2018), per Business Quant data.